Nucleus Genomics has secured a strategic investment from Samsung Next, adding to its recent $14 million Series A round led by Founders Fund and Seven Seven Six, with participation from Neo and Balaji Srinivasan. The company operates a clinical-grade whole-genome sequencing platform.
Nucleus offers a $499 physician-ordered test that sequences close to 100% of a patient’s DNA. The test screens for more than 2,000 diseases and conditions and is carried out through a CLIA-certified, CAP-accredited laboratory in the United States. The company has also acquired Cambrean, an AI-powered wearable health platform, in a move to link continuous biometric data with genetic baselines to provide more personalised health insights.
Samsung Next said Nucleus stood out for “its scientific rigor, delivering validated clinical-grade results rather than entertainment-grade ancestry estimates” and for its potential to act as a genetic baseline layer that can help interpret data from wearables and health sensors.
The latest investment points to a shift in how Nucleus is positioning its business. The company first attracted attention, and controversy, in the fertility sector with its Nucleus Embryo product, launched in 2025 in partnership with Genomic Prediction. The software went beyond standard embryo screening for chromosomal abnormalities, enabling IVF patients to compare embryos based on traits including appearance, cognitive ability and mental health characteristics, raising wider ethical questions about the limits of genetic medicine.
Following the Samsung Next investment and the acquisition of Cambrean, Nucleus appears to be broadening its focus from embryo selection towards a wider preventive health genomics platform. Fertility is now one of several use cases, alongside partnerships with Bryan Johnson’s Don’t Die longevity programme and work with U.S. and international fertility clinics.
